4 results match your criteria: "C-ENDO Diabetes and Endocrinology Clinic Calgary[Affiliation]"
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
N Engl J Med
August 2025
C-ENDO Diabetes and Endocrinology Clinic Calgary, Calgary, AB, Canada.
Article Synopsis
- Cagrilintide and semaglutide, used together (CagriSema), are being tested for weight loss in adults with type 2 diabetes, in a study where over 1,200 participants were randomly assigned to receive either the drug combination or a placebo.
- After 68 weeks, the group receiving CagriSema experienced an average weight loss of 13.7%, significantly higher than the 3.4% weight loss in the placebo group, with many patients achieving at least 5% weight reduction.
- Additionally, more individuals in the CagriSema group reached healthier blood sugar levels, while gastrointestinal side effects were more common among those taking the drugs compared
Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years.
Alzheimers Dement (N Y)
May 2025
Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA.
Introduction: The evoke/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluate safety considerations with semaglutide in adults ≥ 65 years.
Methods: Adverse event (AE) data from three semaglutide phase 3a programs in participants ≥ 65 years with type 2 diabetes and/or overweight/obesity were pooled.
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
Diabetes Obes Metab
April 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Aims: This analysis evaluated whether gastrointestinal (GI) adverse events (AEs) including nausea, vomiting, diarrhoea (N/V/D) and dyspepsia were associated with weight reduction with tirzepatide across the SURMOUNT-1 to -4 trials.
Materials And Methods: SURMOUNT-1 to -4 were global Phase 3 clinical trials evaluating the safety and efficacy of tirzepatide among participants with obesity or overweight with or without type 2 diabetes (T2D). Participants were randomly assigned to receive once weekly subcutaneous tirzepatide or placebo.
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Lancet
March 2021
University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address:
Background: This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweight or obesity, and type 2 diabetes.
Methods: This double-blind, double-dummy, phase 3, superiority study enrolled adults with a body-mass index of at least 27 kg/m and glycated haemoglobin 7-10% (53-86 mmol/mol) who had been diagnosed with type 2 diabetes at least 180 days before screening. Patients were recruited from 149 outpatient clinics in 12 countries across Europe, North America, South America, the Middle East, South Africa, and Asia.